Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.

Revista medica de Chile - 1 Nov 2020

Finsterer Josef

Abstract excerpt

MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after using interferon without benefit. Shortly after starting trametinib/dabrafenib, she experienced an inability to abduct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Imidazoles
Share to Oximes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridones

Share to Pyrimidinones

Share to Renal Insufficiency

Share to Rhabdomyolysis

Share to Vision Disorders

Source

Identifiers

PMID: 33844777
DOI: 10.4067/S0034-98872020001101684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.PMID 33844777Read ↗

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.Semantic proximity Read ↗

Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.Semantic proximity Read ↗

Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.Semantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.Semantic proximity Read ↗

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.Semantic proximity Read ↗

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.Semantic proximity Read ↗

Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.Semantic proximity Read ↗

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.Semantic proximity Read ↗

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report.Semantic proximity Read ↗

Ocular toxicity due to Trametinib and DabrafenibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.